Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Co N.V. (NAMS) Through Open Market Sales
SEC Form 4 Filing
Forbion-affiliated entities, including ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., and Forbion Growth Opportunities Fund I Cooperatief U.A., executed sales of NewAmsterdam Pharma Co N.V. ordinary shares on December 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- ForGrowth NAP B.V., along with affiliated Forbion funds, reported the sale of NewAmsterdam Pharma Co N.V. (NAMS) ordinary shares on December 26 and 27, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 28, 2024.
- On December 26, 2024, 33,438 shares were sold at a weighted average price of $26.0072, with individual transactions ranging from $25.705 to $26.25.
- On December 27, 2024, 41,472 shares were sold at a weighted average price of $25.9522, with individual transactions ranging from $25.75 to $26.325.
- Following these transactions, ForGrowth NAP B.V. beneficially owns 10,686,018 ordinary shares.
- The shares are held directly by ForGrowth on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. and through PoolCo, allocated to Forbion Growth Opportunities Fund I and Forbion Capital Fund IV Cooperatief U.A.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document primarily reports transactions related to share sales under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's performance or future prospects.
Industry Context
This filing indicates activity by a major shareholder, Forbion, in managing its investment in NewAmsterdam Pharma. Such transactions are common and can be driven by various factors, including portfolio rebalancing or profit-taking.
Stakeholder Impact
- The share sales by Forbion may have a minor impact on shareholders due to the increased supply of shares in the market.
- The impact is likely limited as the sales were conducted under a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| 2024-03-28 | NAP PoolCo B.V. adopted a Rule 10b5-1 trading plan. |
| 2024-12-26 | ForGrowth NAP B.V. sold 33,438 ordinary shares at a weighted average price of $26.0072. |
| 2024-12-27 | ForGrowth NAP B.V. sold 41,472 ordinary shares at a weighted average price of $25.9522. |
| 2024-12-30 | Date of signatures for the Form 4 filings. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.